Loading…
ETOPOSIDE is a brand name for Etoposide, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
Please see 3 Serious Warnings and Precautions Box. General The physician must evaluate the need and usefulness of the drug against the risk of adverse reactions. Most such adverse reactions are reversible if detected early. If severe reactions occur, the drug should be reduced in dosage or discontinued, and appropriate corrective measures should be taken according to the clinical judgement of the physician.
Reinstitution of etoposide therapy should be carried out with caution, and with adequate consideration of the further need for the drug and alertness to the possible recurrence of toxicity. As with any potent antineoplastic drug, the benefit to patient versus the risk of toxicity must be carefully weighed.
Carcinogenesis and Mutagenesis Carcinogenicity tests with etoposide have not been conducted in laboratory animals. Given its mechanism of action, it should be considered as a possible carcinogen in humans. The occurrence of acute leukemia, which can occur with or without a pre-leukemic phase, has been reported rarely in patients treated with etoposide in association with other antineoplastic drugs.
Neither the cumulative risk, nor the predisposing factors related to the development of secondary leukemia are known. The roles of both administration schedules and cumulative doses of etoposide have been suggested but have not been clearly defined.
An 11q23 chromosome abnormality has been observed in some cases of secondary leukemia in patients who have received epipodophyllotoxins. This abnormality has also been seen in patients developing secondary leukemia after being treated with chemotherapy regimens not containing epipodophyllotoxins and in leukemia occurring de novo.
Another characteristic that has been associated with secondary leukemia in patients who have received ETOPOSIDE INJECTION Page 8 of 36 epipodophyllotoxins appears to be a short latency period, with average median time to development of leukemia being approximately 32 months.
Cardiovascular Transient hypotension following rapid intravenous administration has been reported in 1% - 2% of patients. It has not been associated with cardiac toxicity or electrocardiographic changes. No delayed hypotension has been noted.
To prevent this occurrence, it is recommended that etoposide be administered by slow intravenous infusion over a 30 to 60 minute period. Hypotension usually responds to cessation of the infusion and/or other supportive therapy as appropriate.
When restarting the infusion, a slower administration rate should be used. Contamination Professional staff administering etoposide should exercise particular care to prevent spillage and self-contact with the drug. Skin reactions, at times severe, associated with accidental exposure to ETOPOSIDE INJECTION may occur.
Gloves should be worn by anyone handling the drug. If etoposide solution contacts the skin, immediately wash thoroughly with soap and water. If etoposide solution contacts mucous membranes, flush thoroughly with water. Materials used for cleaning accidental spills should be disposed of by incineration Driving and Operating Machinery No studies on the effects on the ability to drive and use machines have been performed.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Etoposide in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Etoposide may cause adverse reactions that affect the ability to drive and use machines such as fatigue, somnolence, nausea, vomiting, cortical blindness, hypersensitivity reactions with hypotension. Patients who experience such adverse reactions should be advised to avoid driving or using machines.
Endocrine and Metabolism Tumour lysis syndrome (sometimes fatal) has been reported following the use of etoposide in association with other chemotherapeutic drugs. Close monitoring of patients is needed to detect early signs of tumour lysis syndrome, especially in patients with risk factors such as bulky treatment-sensitive tumours, and renal insufficiency.
Appropriate preventive measures should also be considered in patients at risk of this complication of therapy. Hematologic Fatal myelosuppression has been reported following etoposide administration. Patients being treated with etoposide must be frequently observed for myelosuppression both during and after therapy.
Dose-limiting bone marrow suppression is the most significant toxicity associated with etoposide therapy. The following studies should be obtained at the start of therapy and prior to each subsequent dose of etoposide: platelet count, hemoglobin, white blood cell count and differential.
ETOPOSIDE INJECTION Page 9 of 36 A white blood cell count of between 2,000 – 3,000 cells/mm3 suggests that the dose of etoposide should be reduced by 50%. Platelet counts between 75,000 - 100,000 cells /mm3 require a dosage reduction of 50%.
Platelet counts between 75,000 - 100,000 cells/mm3 require a dosage reduction of 50%. Should the neutrophil count fall below 500 cells/mm3 or the platelet count fall below 50,000 cells/mm3, etoposide should be discontinued and should not be resumed until counts have returned to normal Myelosuppression is dose related and dose limiting, with granulocyte nadirs occurring 7 to 14 days and platelet nadirs occurring 9 to 16 days after drug administration.
Bone marrow recovery is usually complete by day 20, and no cumulative toxicity has been reported. Hepatic/Biliary/Pancreatic Liver function should be regularly monitored. Patients with low serum albumin may be at increased risk for etoposide-associated toxicities.
Infections Bacterial infection must be brought under control before the administration of etoposide therapy because of the risk of septicemia. Immune Concomitant use of etoposide with a live virus vaccine may potentiate the replication of the vaccine virus and/or may increase the adverse reaction of the vaccine virus because normal defense mechanisms may be suppressed by etoposide.
Vaccination with a live vaccine in a patient taking etoposide may result in severe infection. Patient's antibody response to vaccines may be decreased. The use of live vaccines […]